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PREDICTION OF ACUTE GVHD FOLLOWING NONMYELOABLATIVE CON-
DITIONINGBYMEASUREMENTOF TUMORNECROSIS FACTOR-RECEPTOR
1 (TNFR1) AT BASELINE AND AT DAY 7 AFTER TRANSPLANTATION
Humblet-Baron, S., Willems, E., Dengis, O., Seidel, L., Beguin, Y.,
Baron, F. University of Liege, Belgium
Acute graft-versus-host disease (GVHD) has remained a signifi-
cant cause of nonrelapse mortality after allogeneic hematopoietic
cell transplantation (HCT) with nonmyeloablative conditioning.
The role of tumor necrosis factor-alpha (TNF-a) in the biology
of acute GVHD following nonmyeloablative conditioning has not
been studied thus far. Here, we measured TNF receptor 1
(TNFR1) as a surrogate marker for TNF-a in 106 patients before
the start of the conditioning regimen (baseline) and 7 days after al-
logeneic HCT following nonmyeloablative conditioning. The non-
myeloablative regimen consisted of 2 Gy total body irradiation
(TBI) alone (n5 15), 2 Gy TBI plus fludarabine 90 mg/m2
(n5 73), or 4 Gy TBI plus fludarabine 90 mg/m2 (n5 18).
TNFR1 levels increased significantly from baseline to day 7 after
nonmyeloablative HCT (P\0.0001). Patients conditioned with
4 Gy TBI had higher TNFR1 day 7/baseline ratio than those con-
ditioned with 2 Gy TBI (median 1.65 versus 1.25; P5 0.01). Pa-
tients with grade II-IV acute GVHD had higher relative (defined
as TNFR1 level divided by baseline TNFR1 level) TNFR1 levels
than those without grade II-IV acute GVHD on day 7 (NS), and
on day 35 after HCT (P5 0.04), but not on day 63 after HCT.
In a multivariate Cox model, high TNFR1 day7/baseline ratio
was associated with grade II-IV (HR5 2.2, P5 0.01) and grade
III-IV (HR5 2.9, P5 0.007) acute GVHD, but had no impact
on overall survival (P5 0.8). In summary, our data suggest that
nonmyeloablative conditioning induce the generation of TNF-a,
and that the magnitude of TNF-a generation depends on the con-
ditioning intensity (2 Gy versus 4 Gy TBI). Further, assessment of
TNFR1 levels before and on day 7 after nonmyeloablative HCT
provided useful information on subsequent risk of experiencing
acute GVHD.398
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We have previously shown that CD103, an integrin conferring
specificity for the epithelial ligand E-cadherin, is required for donor
CD8 mediated intestinal GVHD. Owing to the lack of E-cadherin
expression on hematopoietic cells, we hypothesized that CD103 de-
ficiency would attenuate GVHD, while sparing GVL effects.
Methods:To examine the role of CD103 in CD8mediatedGVHD,
lethally irradiated A/J hosts (H-2a) were reconstituted by 1.0  107
BALB/c (H-2d), bone marrow cells (BMCs) and 1.0  107 alloanti-
gen-primed CD8 T cells from either WT or CD103-/- mice. To
test whether CD103 deficiency compromises GVL effects mediated
by donorT cells, 2.0 107 splenocytes fromCD103-/- orWTBalb/
c (H-2d) mice were co transferred into BALB.scid (H-2d) recipients,
together with 1.0 107 splenocytes from a Em-TCL1 mouse (H-2b)
with end-stage chronic lymphocytic leukemia (CLL). A control
group received CLL cells alone. T cells from the Em-TCL1 spleno-
cytes were depleted to prevent alloreactivity against BALB.scid
recipients.
Results:Upon adoptive transfer into A/J recipient mice, primed
WT CD8 T cells elicited severe GVHD resulting in 75%
GVHD mortality. In contrast, CD103-/- CD8 T cells elicited
mild or undetectable GVHD (23% GVHD mortality). At au-
topsy compared to the CD103-/- recipients, WT CD8 recipi-
ents exhibited severe lesions in the intestinal and hepatic
epithelium. These data demonstrate that CD103 expression is
required for GVHD pathogenesis mediated by primed CD8 T
cells in this model. To assess the role of CD103 in effectorT cell mediated GVL effects, splenocytes from either WT or
CD103-/- BALB/c mice were adoptively transferred in BALB.s-
cid mice along with CLL cells from Em-TCL1. A control group
of BALB.scid mice received CLL cells only. FACS analyses of
peripheral blood revealed development of CLL in BALB-scid
mice receiving only CLL cells as early as day +14 post cell
transfer. In contrast no CLL was detected in peripheral blood
of mice receiving WT or CD103-/- splenocytes at any time
point. BALB.scid mice receiving CLL cells only, displayed
poor grooming, decreased activity, dyspnea and massive heptos-
plenomegaly. Mean survival time of BALB.scid mice in CLL
only group was 73 days. In contrast all the mice receiving
WT or CD103-/- cells survived beyond day +110 with no evi-
dence of CLL (p-value5 0.0001).
Conclusion:Our data demonstrate that CD103 deficiency atten-
uates GVHD while sparing GVL effects and thus hold great
translational potential.
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Adoptive transfer of co-stimulated T cells represents an immu-
notherapeutic method currently under clinical investigation. We
hypothesized that the ex vivo acquisition of rapamycin resistance
and type I cytokine polarization during co-stimulation would
augment the in vivo effect of adoptively transferred human T
cells. In the presence of rapamycin, T cell co-stimulation and
polarization with IL-12 or IFN-g permitted human CD4+ and
CD8 +T cell differentiation towards a Th1/Tc1 phenotype: by
intracellular flow, median percentage expression of Foxp3, IFN-
g, and T-bet was 4%, 20%, and 72%, respectively. Phospho-
flow cytometry revealed that such Th1/Tc1 cells expressed
activated STAT1 and STAT4 in spite of mTOR blockade;
STAT activation was abrogated by PI3 kinase inhibition. Rapa-
mycin-resistant human Th1/Tc1 cells (Th1/Tc1.R cells): (1)
had increased expression of the autophagy-related gene LC3BII
by gene array and protein analysis; (2) preferentially expressed
anti-apoptotic bcl-2 family members (reduced Bax, Bak; increased
phospho-Bad); (3) maintained mitochondrial membrane poten-
tials; and (4) had reduced apoptosis relative to control Th1/
Tc1 cells not generated in rapamycin (p5 0.04). The anti-apo-
ptotic phenotype of Th1/Tc1.R cells was abrogated by co-incu-
bation with the autophagy inhibitor, 3-methyl adenine. The in
vivo effect of the Th1/Tc1.R cells was evaluated using two xeno-
geneic GVHD (x-GVHD) models. First, in an LPS-induced
x-GVHD model, Th1/Tc1.R cells resulted in lethality in 75%
recipients; soluble TNF-a receptor therapy with etanercept re-
duced the frequency of lethality to 15%. Second, using a non-
LPS natural history model of x-GVHD, recipients of Th1/
Tc1.R cells (relative to recipients of control Th1/Tc1 cells)
had increased human T cell engraftment (day 30 post-BMT,
p5 0.001), increased human T cell cytokine levels, increased hu-
man T cell expression of the cytotoxic degranulation molecule
CD107 (p5 0.05), and increased human T cell infiltration of
skin, gut, and liver. In this model, lethality due to x-GVHD
was also increased in Th1/Tc1.R cell recipients (lethality in-
creased from 20% to 70%, p5 0.04). We conclude that rapamy-
cin therefore does not impair human T cell capacity for type I
differentiation. Rather, by promoting autophagy rapamycin per-
mits stable expression of T-bet and generates an anti-apoptotic
Th1/Tc1 effector phenotype, thereby yielding increased
x-GVHD.400
B- CELL DEPLETION AS THERAPY FOR STEROID REFRACTORY CHRONIC
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